GLP-1 receptor agonists in cardiometabolic disease: a meta-analysis of 102,486 patients
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may provide cardiovascular benefits beyond glycaemic control. This meta-analysis evaluated their effects on cardiovascular and related clinical outcomes. PubMed, Cochrane Library, and Google Scholar were searched up to March 20, 2026, for randomized controlled trial...